Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Rhea-AI Summary

Revive Therapeutics (OTCQB: RVVTF; CSE: RVV) provided an update on its collaborative research study with Defence R&D Canada – Suffield Research Centre (DRDC) evaluating Bucillamine as a potential treatment for nerve agent–induced brain injury. The company said the DRDC-led study is expected to conclude with results in January 2026. Any findings will be released only with the express authorization of DRDC. Revive indicated it will continue to provide updates as the study advances toward completion.

News Market Reaction

-21.09%

1 alert

-21.09% News Effect

On the day this news was published, RVVTF declined 21.09%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical countermeasures. DRDC is evaluating pharmacological compounds, including Bucillamine, that may mitigate nerve agent–induced brain injury.

After recent discussions with the DRDC, the research study on Bucillamine is expected to conclude with results in January 2026. Any findings from the study will be released only with the express authorization of DRDC. Revive will continue to provide updates on the DRDC study as it advances toward completion.

About Revive Therapeutics Ltd.

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. For more information, visit www.ReviveThera.com.

For more information, please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three months ended September 30, 2025 ("MD&A"), dated November 25, 2025, which is available on the Company's profile at www.sedarplus.ca.

FAQ

What is Revive Therapeutics announcing about the Bucillamine nerve agent study (RVVTF)?

Revive said the DRDC-led study of Bucillamine is ongoing and is expected to conclude with results in January 2026.

When will DRDC release results for the Bucillamine nerve agent study related to RVVTF?

The study is expected to conclude with results in January 2026, and any findings will be released only with DRDC's express authorization.

Who is conducting the Bucillamine nerve agent research with Revive (RVVTF)?

The study is being conducted by Defence R&D Canada – Suffield Research Centre (DRDC) in collaboration with Revive.

How will Revive (RVVTF) share updates about the DRDC Bucillamine study?

Revive will provide periodic updates as the DRDC study advances and will report results only after DRDC authorizes their release.

Does the December 15, 2025 update from Revive (RVVTF) include study results or clinical data?

No. The update reports timing and collaboration details only; no study results or clinical data were included.

How should investors follow the DRDC Bucillamine study progress for RVVTF?

Investors should monitor Revive's public updates and official DRDC authorizations for the expected January 2026 results release.